文献速递神经肿瘤

儿童头癣放疗后诱发的脑膜瘤立体定向放射外科治疗结局:与散发性脑膜瘤的比较研究

Stereotactic Radiosurgery Outcomes for Radiation-Induced Meningiomas After Childhood Tinea Capitis Irradiation: A Comparative Study with Sporadic Meningiomas.
PubMed 文献 · Neuro Oncol · 2026-08-10

本研究比较儿童期因头癣接受头皮放疗后诱发的脑膜瘤与散发性脑膜瘤接受立体定向放射外科(SRS)治疗的体积反应。2010-2023年539例SRS治疗脑膜瘤患者中204例纳入体积分析,61例(29.9%)有头癣放疗史。结果显示头癣放疗组多发脑膜瘤更常见(73.8% vs 11.9%,P < .001),且独立预测较差的体积反应(相对体积变化增加38.7%,P = .026),但无进展生存无差异。

要点

  • 儿童头癣放疗相关脑膜瘤多为多发(73.8% vs 11.9%,P < .001)。
  • 头癣放疗史独立预测SRS后较差的体积反应(+38.7%相对体积变化,P = .026)。
  • 两组手术切除需求(P = .535)和无进展生存无显著差异。

核心结论

  • 儿童头癣放疗相关脑膜瘤以多灶性为特征,对SRS的体积反应较差,提示可能为治疗抵抗表型,需个体化管理。

研究设计与样本

  • 回顾性比较研究,纳入2010-2023年539例SRS治疗脑膜瘤患者中204例符合体积分析标准者,中位随访64.6个月(IQR 32.8-107.8)。
  • 61例(29.9%)有儿童期头癣头皮放疗史,143例(70.1%)无既往颅脑放疗史。

主要发现

  • 头癣放疗组年龄更大(中位67.6 vs 62.8岁,P < .001),多发脑膜瘤更常见(73.8% vs 11.9%,P < .001)。
  • 基线肿瘤体积两组相似(P = .516),手术切除需求相似(P = .535)。
  • 多变量分析显示头癣放疗独立预测较差的体积反应(相对体积变化增加38.7%,P = .026),达到研究定义「良好反应」的可能性较低但未达统计学显著性。
  • 头癣放疗与无进展生存无关。

关键数值与推荐

  • 研究定义「良好反应」为肿瘤体积缩小≥29%。
  • 体积变化基于T1加权钆增强MRI基线及末次随访或术前测量。

临床怎么用

  • 对儿童期头癣放疗相关脑膜瘤患者,SRS后应预期体积缩小可能较慢,需加强影像随访。
  • 多发病灶常见,治疗决策需个体化,结合多学科评估。

局限性

  • 回顾性研究,样本来自单中心SRS队列,体积分析仅纳入204/539例。
  • 「良好反应」差异未达统计学显著性,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Childhood scalp irradiation for tinea capitis (TC) increases the long-term risk of intracranial meningiomas. It remains unclear whether prior TC irradiation affects meningiomas' response to stereotactic radiosurgery (SRS). We compared TC-irradiated and sporadic meningiomas treated with SRS. METHODS: Among 539 meningioma patients treated with SRS from 2010-2023, 204 met criteria for volumetric analysis (median follow-up 64.6 months, IQR 32.8-107.8). Of these, 61 (29.9%) had childhood scalp irradiation for TC, while 143 (70.1%) had no prior cranial irradiation. Tumor volumes were measured on T1-weighted gadolinium-enhanced MRI baseline and at last follow-up, or prior to surgery. Treatment response was assessed as percent volume change, as a binary study-defined "good response" (≥29% reduction), and RANO-aligned categories. Predictors of response and surgical intervention were evaluated using multivariable regression. RESULTS: TC-irradiated patients were older (median 67.6 vs. 62.8 years, P < .001) and more commonly had multiple meningiomas (73.8% vs. 11.9%, P < .001) than non-irradiated patients. Baseline tumor volume was similar between groups (P = .516), as was the need for surgical resection (P = .535). Multivariable analysis showed that TC irradiation independently predicted poorer volumetric response (a + 38.7% relative volume change, P = .026) and a lower likelihood of achieving the study-defined "good response," although this was not statistically significant. TC irradiation was not associated with progression-free survival. CONCLUSIONS: Childhood TC irradiation-related meningiomas are a distinct subgroup characterized by multifocality and reduced volumetric response to SRS. These findings suggest a potentially treatment-resistant phenotype, supporting the need for individualized management. Childhood radiation therapy for tinea capitis was once widely used and is now known to increase the long-term risk of developing brain tumors, specifically meningiomas. Many patients later present with multiple tumors requiring treatment. Stereotactic radiosurgery (SRS) is a noninvasive treatment that delivers highly focused radiation to the tumor. However, its specific effectiveness for radiation-induced tumors remains unclear. In this study, we compared radiation-induced and sporadic meningiomas treated with SRS. We found that radiation-induced tumors were more often multiple and showed less shrinkage after treatment, although overall disease control was similar, suggesting the need for closer monitoring and individualized care.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ben-Mouel OS, Shemesh SZ, Dumanis G, et al. Stereotactic Radiosurgery Outcomes for Radiation-Induced Meningiomas After Childhood Tinea Capitis Irradiation: A Comparative Study with Sporadic Meningiomas. Neuro Oncol. 2026. PMID: 42573510. doi:10.1093/neuonc/noag180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。